Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Neta Goldfeiz"'
Autor:
Lilach Moyal, Nataly Feldbaum, Neta Goldfeiz, Ada Rephaeli, Abraham Nudelman, Michal Weitman, Nataly Tarasenko, Batia Gorovitz, Leah Maron, Shiran Yehezkel, Iris Amitay-Laish, Ido Lubin, Emmilia Hodak
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146115 (2016)
The 2 histone deacetylase inhibitors (HDACIs) approved for the treatment of cutaneous T-cell lymphoma (CTCL) including mycosis fungoides/sezary syndrome (MF/SS), suberoylanilide hydroxamic acid (SAHA) and romidepsin, are associated with low rates of
Externí odkaz:
https://doaj.org/article/9ab3cb25672a40d497fe1695f1a53697
Autor:
Yael Ziv, Lilach Moyal, Nataly Tarasenko, Abraham Nudelman, Emmilia Hodak, Efrat Tal, Ada Rephaeli, Batia Gorovitz, Neta Goldfeiz
Publikováno v:
Investigational New Drugs. 36:1-9
We previously found that the novel histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) had greater selectivity against cutaneous T-cell lymphoma (CTCL) than SAHA. AN-7 synergizes with doxorubicin (Dox), an anthracycline an
Autor:
Ido Lubin, Emmilia Hodak, Batia Gorovitz, Lilach Moyal, Nataly Tarasenko, Nataly Feldbaum, Ada Rephaeli, Iris Amitay-Laish, Michal Weitman, Neta Goldfeiz, Abraham Nudelman, Leah Maron, Shiran Yehezkel
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 1, p e0146115 (2016)
PLoS ONE, Vol 11, Iss 1, p e0146115 (2016)
The 2 histone deacetylase inhibitors (HDACIs) approved for the treatment of cutaneous T-cell lymphoma (CTCL) including mycosis fungoides/sezary syndrome (MF/SS), suberoylanilide hydroxamic acid (SAHA) and romidepsin, are associated with low rates of